HCPCS Level II code C1607 identifies an integrated, rechargeable implantable neurostimulator system that includes all implantable and external components and the charging system. This device-level code matters nationally because implantable neurostimulation is an important therapeutic option for chronic pain, movement disorders, and other neurologic indications; precise coding supports device tracking, billing consistency, and payer coverage decisions.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how C1607 is defined, typical sites of service where the device is implanted and managed, and the clinical context for use. The publication summarizes available national benchmarks for device utilization and reimbursement trends, highlights recent policy and coverage considerations affecting implantable neurostimulation systems, and outlines common documentation and coding considerations relevant to billing and claims submission.

The content is intended for clinicians, billing professionals, and policy analysts seeking a national-level briefing on C1607: what the code represents, who pays for these devices, and which operational and policy issues to expect when billing for integrated, rechargeable implantable neurostimulators.